Masaya Inagaki

Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose–response study and open-label extension study

Takashi Wada, Masaya Inagaki, Toru Yoshinari et al. · Clinical and Experimental Nephrology · 2020 · 87 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +17

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan

Takashi Wada, Kazumi Mori‐Anai, Akiko Takahashi et al. · Journal of Diabetes Investigation · 2022 · 28 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +16

Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study

Takeshi Okanoue, Michiie Sakamoto, Kenichi Harada et al. · Hepatology Research · 2021 · 27 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Association between glycemic control and cardiovascular events in older Japanese adults with diabetes mellitus: An analysis of the Japanese medical administrative database

Koutaro Yokote, Ryo Suzuki, M. Wafik Gouda et al. · Journal of Diabetes Investigation · 2021 · 11 citations · Full text

Medicine, Geriatric Medicine, Internal Medicine +15

Effect of sodium–glucose cotransporter 2 inhibitor medication on new prescriptions of antihypertensives, antigout/antihyperuricemics and antidyslipidemics in Japan: Analysis using the <scp>JMDC</scp> Claims Database

M. Wafik Gouda, Kenji Arakawa, Masaya Inagaki et al. · Journal of Diabetes Investigation · 2022 · 10 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17